Inhibiting the release of Apelin peptide by cancer cells leads to an increase in pro-inflammatory responses in co-cultured macrophages, resulting in a significant upregulation of genes like IL-1β, IL-6, and TNF-α, along with a marked reduction in anti-inflammatory cytokine levels. This evidence concerns the gene APLN and cancer.